A Prospective, US Multicenter Open Label Study in the Treatment of Hepatocellular Carcinoma (HCC) With a Radiopaque (RO) Bead (LC Bead LUMI) Loaded With Doxorubicin
Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 21 Aug 2018
Price : $35 *
At a glance
- Drugs Doxorubicin (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors BTG International
- 31 Aug 2018 Biomarkers information updated
- 09 Aug 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 13 Apr 2018 Planned initiation date changed from 1 Apr 2018 to 1 Jul 2018.